Development

History of Drug Development

JCR’s history of drug development is marked by continued challenge.
In 2010, JCR obtained marketing approval in Japan for a biosimilar for the treatment of renal anemia. At the time of filing, there were no domestic guidelines and no formal regulatory pathway for biosimilars.
In 2015, JCR became the first company in Japan to receive marketing approval for an allogeneic regenerative medicine product. This achievement was built on years of sustained research and development (R&D) and manufacturing efforts that began in the early 2000s, when cell based products were still rare.

JCR has also prioritized rare diseases, focusing on areas with very small patient populations. In 2021, JCR obtained marketing approval in Japan for LSD therapy applying its proprietary BBB penetration technology. It was the first approved medicine in the world to use this approach.

Today, JCR has expanded beyond Japan, establishing a global development framework and conducting clinical trials worldwide. Rare disease patients live across the globe, many without available treatments. JCR remains committed to advancing drug development to bring new therapeutic options to patients worldwide.